GP Pharm, S.A. – Product Pipeline Review

Global Markets Direct’s, ‘GP Pharm, S.A. – Product Pipeline Review – 2016’, provides an overview of the GP Pharm, S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GP Pharm, S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of GP Pharm, S.A.

The report provides overview of GP Pharm, S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses GP Pharm, S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features GP Pharm, S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate GP Pharm, S.A.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for GP Pharm, S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding GP Pharm, S.A.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

GP Pharm, S.A. Snapshot 4

GP Pharm, S.A. Overview 4

Key Facts 4

GP Pharm, S.A. - Research and Development Overview 5

Key Therapeutic Areas 5

GP Pharm, S.A. - Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products - Monotherapy 8

GP Pharm, S.A. - Pipeline Products Glance 9

GP Pharm, S.A. - Early Stage Pipeline Products 9

Preclinical Products/Combination Treatment Modalities 9

GP Pharm, S.A. - Drug Profiles 10

leuprolide acetate - Drug Profile 10

Product Description 10

Mechanism Of Action 10

R&D Progress 10

octreotide acetate MAR - Drug Profile 11

Product Description 11

Mechanism Of Action 11

R&D Progress 11

Pegylated Doxorubicin - Drug Profile 12

Product Description 12

Mechanism Of Action 12

R&D Progress 12

risperidone depot - Drug Profile 13

Product Description 13

Mechanism Of Action 13

R&D Progress 13

GP Pharm, S.A. - Pipeline Analysis 14

GP Pharm, S.A. - Pipeline Products by Target 14

GP Pharm, S.A. - Pipeline Products by Route of Administration 15

GP Pharm, S.A. - Pipeline Products by Molecule Type 16

GP Pharm, S.A. - Pipeline Products by Mechanism of Action 17

GP Pharm, S.A. - Dormant Projects 18

GP Pharm, S.A. - Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 20

Appendix 21

Methodology 21

Coverage 21

Secondary Research 21

Primary Research 21

Expert Panel Validation 21

Contact Us 21

Disclaimer 22

List of Tables

List of Tables

GP Pharm, S.A., Key Facts 4

GP Pharm, S.A. – Pipeline by Indication, 2016 6

GP Pharm, S.A. – Pipeline by Stage of Development, 2016 7

GP Pharm, S.A. – Monotherapy Products in Pipeline, 2016 8

GP Pharm, S.A. – Preclinical, 2016 9

GP Pharm, S.A. – Pipeline by Target, 2016 14

GP Pharm, S.A. – Pipeline by Route of Administration, 2016 15

GP Pharm, S.A. – Pipeline by Molecule Type, 2016 16

GP Pharm, S.A. – Pipeline Products by Mechanism of Action, 2016 17

GP Pharm, S.A. – Dormant Developmental Projects,2016 18

GP Pharm, S.A., Other Locations 20

List of Figures

List of Figures

GP Pharm, S.A. – Pipeline by Indication, 2016 6

GP Pharm, S.A. – Pipeline by Target, 2016 14

GP Pharm, S.A. – Pipeline by Route of Administration, 2016 15

GP Pharm, S.A. – Pipeline by Molecule Type, 2016 16

GP Pharm, S.A. – Pipeline Products by Mechanism of Action, 2016 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports